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Abstract 
Background: Biotechnology is rapidly developing on a global scale. However, some 
evidence indicates that Eastern European (EE) countries are not fulfilling their 
potential in this field. Objectives: This paper aims to examine whether selected EE 
countries are able to develop a strong biotechnology industry. Potential investment 
approaches and the existing but not used or neglected infrastructures in EE countries 
were also examined. Methods/approach: In order to determine biotechnological 
activities in EE countries, indicators such as intellectual property protection, venture 
capital availability, published scientific publications as well as other indicators were 
analyzed. These indicators were compiled and compared between EE countries and 
regions with a rich and diverse biotechnological business sector. Results: The results 
suggest an underdeveloped biotechnology business sector in EE countries, with 
talented but unexploited scientists and unutilized infrastructure. The systematic 
drawbacks of EE countries lead to a hostile investment environment. Conclusions: 
The findings make a significant contribution to understanding how the biotechnology 
industry in EE countries is structured and how investments can be rationally placed. 
EE countries need to adapt their venture capital market for biotechnology ventures. 
Several changes in regulations could have a large impact on biotechnology 
investments. 
 
Keywords: biotechnology; investment; research and development; transition 
countries; Eastern Europe 
JEL classification: O31 
Paper type: Research article 
 
Received: May 07, 2015  
Accepted: Sep 13, 2015 
 
Citation: Vida, P. (2016), “The Potential of Biotechnology Investments in Selected 





The economy can be described as a sequence of transformations in technology 
and policy trough time (Essendorfer et al., 2015). During the transformation old 
technologies and procedures are being replaced by newer and more efficient ones. 
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These transformations are creating waves of expanding and contracting gross 
domestic product of an economy. The benefits of an expanding economy are not 
shared equally (Kogan et al., 2015). To obtain the benefits of an expanding 
economy, accessibility of new and efficient technologies are crucial. Among the 
various new technologies, this study focuses on biotechnology. The aim of this study 
is to compare a set of regions, with a well-developed biotechnology business sector, 
with a group of selected Eastern European countries.  
 The impact of products from biotechnological companies on different aspects of 
the society is surprisingly large (Kishore & Shewmaker, 1999). This impact on society 
has motivated researchers to investigate how to launch, finance and manage 
biotechnological companies. Typically, biotechnological companies strongly cluster 
(geographically) with universities and other biotechnological companies. This is a 
specialty of biotechnological in a surrounding of globalization of businesses and 
scientific research (Boschma et al., 2014).  
 Among the dedicated biotechnological companies we will focus on companies 
whose main area of activity is health care or medicine. We have selected these 
particular industries, since they are the most challenging part of the 
biotechnological sector, and are also highly capital intensive (Junkunc, 2007).  
In our paper we focus on following selected Eastern European (EE) countries: 
Bulgaria, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, 
Slovakia and Slovenia. Above motioned ten countries share history of transition from 
centrally planned economy to market economy. In addition, and more recently, 
these countries became members of European Union (EU). This paper investigates 
the biotechnological landscape in the EE countries. Moreover, the paper is 
reviewing the use of the existing scientific and business infrastructure. 
 A goal of the paper is also to compare the development of biotechnology in EE 
countries with more developed regions and countries. We have selected following 
three regions with a well-developed biotechnology business sector: the Boston area, 
Switzerland and Singapore. We have selected these regions in order to cover diverse 
regions on different continents with a wide range of cultural and historical 
background. The approaches to the biotechnological business sector in these three 
regions are very different. Each of these three success stories is unique, but they also 
have some common themes, which will be investigated.  
 The paper is divided in seven sections. The first section serves as an introduction; 
the second part gives a definition of the term biotechnology and an historic 
overview of its development. The third section shows three internationally successful 
biotechnology regions. The following three sections are focusing on the local 
biotechnological surroundings in the EE countries. The fourth section focuses on the 
current situation of biotechnology investments in the selected EE countries; the fifth 
section describes the sources of low level biotechnology investments and the sixth 
looks for the potential of growth. The seventh and last section summarizes the ideas 
of this paper with its concluding thoughts.  
 
Origins and development of biotechnology  
The current definition of biotechnology used by the OECD reads as following: “The 
application of science and technology to living organisms, as well as parts, products 
and models thereof, to alter living or non-living materials for the production of 
knowledge, goods and services” (OECD, 2014). 
This section will present a short overview of the terms used in the above definition 
and explain the basic concepts behind the definition. The term biotechnology was 
first described by Károly (Karl) Ereky in 1919 (Ereky, 1919). He described it as the 




combined use of biology and technology for turning raw materials into useful 
products. Ereky envisioned a science based biotechnology, which could hold the 
key to solving social inequities, like famine, energy shortage or health care (Fári & 
Kralovánszky, 2006). According to the OECD definition, humankind has used the 
rudimentary form of biotechnology for millennia in agriculture, food products or 
medicine. Such examples are ancient brewers and bakers using yeast cultures to 
make beer and bread (Hulse, 2004). 
 In this paper the term biotechnology will be used in a more strict modern sense. 
Modern biotechnology is using genetic engendering tools to manipulate cell and 
DNA. Cells are the structural and functional basic biological units of all known living 
organisms. DNA is a long and coiled molecule in the nucleus of the cell, which holds 
the hereditary information. DNA is common to all living things as well as for certain 
viruses. It bears all the necessary instructions for the construction and operation of a 
life-form. The information is stored as the sequence of different nucleotides; 
nucleotides are the building blocks of the DNA molecule. The sequence of the 
different DNA building blocks - the nucleotides, defines the biological properties of 
the DNA molecule. All known organisms have chemically the same four nucleotides, 
but the DNA sequence of every individual differs. The hereditary information unit is 
classically viewed as gene (Pearson, 2006). Genes are sections of the DNA with a 
specific nucleotide sequence (Gerstein et al., 2007). Genes can hold information for 
proteins; therefore the gene sequence controls the properties of a protein. Proteins 
perform most of the structural and functional tasks of a living biological cell. The most 
frequent groups of proteins are: (1) enzymes, can chemically modify other 
compounds by accelerating chemical reactions; (2) signalling proteins, they rely 
messages for example from the outside of the cell to the inside of the cell; (3) 
immune system proteins, protect the organism against disease and other outside 
threats; and (4) structural proteins, which are responsible for the structural integrity of 
an organism. From this short list, the importance of properly working proteins should 
be clear. A malfunctioning or missing key protein can lead to malfunction of the 
affected cell and ultimately to disease (Gregersen et al., 2006). Biotechnology tries 
to apply the knowledge gained from the inner workings of a cell to make useful 
products, improve industrial chemical processes and make better medicine.  
 The work flow of a biotechnological project can be outlined in brief as follows: (a) 
identifying the target gene, which produces the gene product of interest; (b) identify 
and cut the gene fragment from a DNA sequence; (c) place the gene fragment 
into a vector, this a engineered DNA unit, which carries the gene of interest; (d) 
place the vector into a host cell, such as Escherichia coli or mammalian cells, and 
grow them in culture; (e) induce the production of the gene product of interest; and 
(f) extract and purify the gene product of interest (Consortium et al., 2008; Wurm, 
2004). 
 The above described approach perhaps seems cumbersome, but it allows the 
production of molecules that are too complex, too expensive or just impossible to 
produce by chemical synthesis. Among this complex molecules are also 
biopharmaceuticals. The majority of biopharmaceuticals are therapeutic proteins, 
these can be further divided into groups: (i) blood factors; (ii) hormones; (iii) growth 
factors; (iv) monoclonal antibodies(Rader, 2008). 
 The idea that therapeutic proteins could be practically achievable by 
biotechnology methods matured in the beginning of the 1970s. But it needed a 
decade of research and development (R&D) activities before the first products 
could be patented and prepared for the market. One of the first biotechnological 
products, (the early 1980s) was the recombinant human insulin (a hormone) form 
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Genentech that was soon followed by the human growth hormone (from 
Genentech), erythropoietin (a hematopoietic growth factor) by Amgen, just to 
name the first few (Coan & Ron, 2001). After this first wave of biopharmaceuticals in 
the 1980s, came the second wave with more complex products, such as 
monoclonal antibodies in the 1990s (Waldmann, 2003).  
 Now more than 30 years after the market launch of the first biopharmaceutical 
product, the biotechnology industry has been, most of the time, unprofitable in the 
aggregate. This can be credited to the circumstance that the number of emerging 
R&D-phase companies dwarfs the number of profitable enterprises (Ernst & Young, 
2013). The R&D-phase frequently exceeds 10 years and in this period no profits are 
generated. To bridge the time to the market introduction of the product, 
biotechnological companies implement strategies to create other sources of 
income. These strategies include providing services to universities and industry; 
acquiring R&D contracts from governmental and other institutions. Also alliances with 
industrial partners, can have strategic importance (Glick, 2008). The motivations of a 
biotechnological company to establish an alliance with an industrial partner are 
two-fold; the objective is to accelerate the time to product launch and enhance the 
company’s market value.  
 Typical alliances are made between biotechnological companies and 
pharmaceuticals companies (Nicholson et al., 2002). These alliances can lead to 
even closer cooperation and ultimately to mergers or acquisitions. The 
abovementioned company Genentech, merged with a pharmaceutical company 
Roche in 2009. This is an example when a big pharmaceutical company uses the 
know-how of biotechnological companies to augment its drug pipelines. More 
mergers and acquisitions (M&A) followed the following years (Rossi et al., 2013).  
Today, the biotechnological industry has a roughly global revenue of 55.09 ×109 EUR 
and an annual growth of 10% (Bloomberg, 2014). The traditional locations are the US 
and Europe – as Asia is quickly catching up.  
 
Investments in biotechnology sector: Best practices of 
developed regions  
To paint a picture about the investment trends in biotechnology, three regions will be 
compared in this section. The regions were picked based on their geographical 
location and maturity of the biotechnological industry. For the US we have selected 
the Boston area, as it is a traditional biotechnology location. For Europe, we have 
picked Switzerland. Switzerland has favorable conditions for the biotechnological 
industry, and for Asia we chose Singapore. Singapore has a leading position for 
research and contract research companies in Asia Pacific.  
 The three regions are compared based on four indicators: (1) number of students 
enrolled into science and engineering programs, (2) R&D expenditure, (3) average 
number of citation per paper, published in Thomson Reuters-indexed journals from a 
10-year plus 8-month period, and (4) number of publicized scientific articles for each 
given year. The first two indicators are measuring the inputs in to the innovation 
system. The first indicator, the number of students enrolled into science and 
engineering programs relative to 1000 inhabitants, is shown in Figure 1. This metric 
gives an estimate of the possible high skilled workforce for a high-tech business 
sector. The R&D expenditure is presented as a percentage of the regions gross 
domestic product (GDP) and shown in Figure 1 in the right chart. Higher R&D 
expenditure means that more ideas are tested and investigated in different 
laboratories and more knowledge is accumulated. More knowledge can lead to 
new products and even crate new markets. The third and fourth indicators are 




measuring the quality and quantity of the R&D activities. The number of citations for 
a scientific paper is a metric that represents the quality of presented ideas in the 
published papers. In Figure 2, (right chart) the average number of citation per paper 
is shown. Each point is showing the moving average for 10 years. This gives a rough 
estimate on the overall level of quality of the published publications. The last 
indicator is aiming to grasp the size of the R&D activities in the given region. Figure 2, 
(right chart) is showing how many scientific papers a published per 1000 inhabitants 
per year. A higher number suggests more R&D activity.  
 In the following paragraphs, the three regions will be described in more detail. The 




Enrolled into science and engineering study programs and R&D expenditure 
 
Sources: UNSD, 2011; WorldBank, 2014b 
 
The Boston area 
Boston is hosting 33 institutions of higher education (NCES, 2014), among them are 
world known academic institutions and centers of biotechnology excellence. These 
institutions are located in the greater Boston area. Additionally, the greater Boston 
area also has a geographic concentration of business that supports and 
interconnects all aspects of the biotechnology industry including pharmaceuticals, 
medical devices diagnostics and bioinformatics. This network of organizations 
includes more than hundred different kinds of organizations, like biotechnology 
companies, universities, research clinics and other venture capital firms (Owen-Smith 
& Powell, 2006). Best known academic institutions with basic research capabilities 
are for example: Harvard University, University of Massachusetts, Boston University, 
Massachusetts Institute of Technology (MIT) and Tufts University. These institutions also 
offer advanced degrees in biosciences. The highest founded clinics and hospitals 
are: Brigham & Women’s Hospital, Massachusetts General Hospital, Dana-Farber 
Cancer Institute, Beth Israel Hospital, and Children’s Hospital. Multinational 
pharmaceutical firms only recently moved some R&D activities to Boston. 
 A characteristic for the Boston area is a strong linkage between the academic 
research sector and the biotechnological community (Owen-Smith & Powell, 2006). 
Many biotechnological companies have chosen put their central operations or 
administration in Boston, because they want to benefit from the proximity of many 
other biotechnological companies and the prominent academic and research 
institutions. Boston’s intellectual infrastructure is mature with a high number of 
research employees, hospital and medical employees. Boston is well above the US 
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national average. For example, the Boston area average for Science and 
Engineering students per 1000 citizens is about 28, the US national average is around 
10, as shown in Figure 1 in the left chart.  
 Boston has a lot to offer from the financial and political site as well. The State of 
Massachusetts provides ways of reducing taxes for businesses and other offerings to 
support its biotechnological industry. An example is the Massachusetts Life Sciences 
Center (MLSC), this is an state-funded agency that manages the implementation of 
a 10-year, $1-billion (894.4-million €) (MLSC, 2014). Along this specific local state 
funded incentives for biotechnology, there are more general funding opportunities 
for all disciplines of basic research issued from the Federal Government. The State of 
Massachusetts was granted a  $8 billion (7.2 billion €) from federal R&D funds in one 
singe fiscal year 2009 (Yamaner, 2012). This adds to the fact that the R&D 
expenditure of State Massachusetts is among the highest worldwide. R&D 
expenditure amounted to 5.4% (in 2009) of the GDP (Wolfe, 2012) and is well above 
the US average, at 2.9% or Switzerland and Singapore as seen in Figure 1 (right 
chart). The Boston area’s biotechnology sector is well positioned; it can continue to 
provide employment opportunities and attract business and investors.  
 
Figure 2 
Citations of scientific papers (average), and relative number of yearly publicized 
scientific articles 
 
Note: Number of citations is not available for Singapore 
Sources: Schafer, 2011; WorldBank, 2014c 
 
Switzerland 
The most notable strengths that Switzerland can offer are: innovation, labor market 
efficiency and sophistication of its business sector (Schwab & Sala-i-Martín, 2014). The 
scientific research institutions publish a relatively high number of research articles 
(Figure 2, right chart); furthermore the quality of the publications is the highest 
worldwide and is increasing. This is shown on the left chart in Figure 2. This makes 
Switzerland one of the most interesting regions in scientific research. 
 The Swiss Federal Institute of Technology Zurich (ETH) is among the highest ranked 
university in the World. Beside the ETH, the University of Zurich, with its University 
Hospital, has also a high ranking among European universities (ShanghaiRanking, 
2014). All the above mentioned institutions are located in close geographical 
proximity. This is facilitating a rich cooperation between the institutions - 
complementary research and advanced academic programs at the same time. 
Switzerland’s biotechnological companies are showing a vast range of sizes, from 
Multinational Corporation to innovative start-ups. The mains clusters of 




biotechnological companies are located in Basel (BioValley), Zurich and Geneva 
(BioAlps) (JLL, 2012). 
 Biotechnological companies can find assistance for spin-offs in the highly 
concentrated biotechnological industry, universities and government (Zürcher, 
2005). The headquarter of a couple of big pharmaceutical companies in Basel, and 
the strong financial sector in Zurich, also serves as leading powers for new innovation 
and development. Joint activities among academic institutions and the private 
sector create a favourable environment for start-up companies. Universities provide 
affordable laboratory space in the initial years, and later on, biotechnological 
business incubators provide opportunities for further growth (AWA, 2012). 
 Innovation and creativity is abundant in Switzerland, also in a European setting 
(Hollanders & Es-Sadki, 2014). Biotechnology companies are strongly represented 
among the start-up companies in Switzerland, especially because they are 
benefiting from good access to private capital and public funding (EAER, 2014). In 
Switzerland, the Swiss National Science Foundation (SNSF) is the lead provider for 
funding of basic science activities on a federal level. It is funding a broad spectrum 
of disciplines with an annual fund size of 700-million CHF (650.2-million €). The size of 
available capital for biotechnological companies from 2010 to 2012 was $250-million 
(232.2-million €) per annum, including equity financing and non-equity financing 
(loans, grants …). With its dynamic combination of academic institutions, high 
concentration of biotechnological companies and well developed infrastructure, 
Switzerland’s position as a global biotechnological innovator is excellent. 
 
Singapore 
Singapore is a new player in biotechnology and has entered this field in an effort to 
diversify its economy. Singapore is trying to make biotechnology the forth pillar of its 
economy. Singapore is already successful in electronics, chemicals, and precision 
engineering. The country has showed an impressive economic growth in the past 
decades (1960-2013), where the country had an averaging 7% GDP growth per 
annum (WorldBank, 2014a). Such rapid growth could not be achieved without 
continuous industrial restructuring and technological upgrading. A further step in this 
direction was the announcement of the National Biomedical Science (BMS) Strategy 
in 2000. This strategy was a 5-year project including new institutes, academic 
research, and training in biotechnology as well as a tax incentive for both 
multinational pharmaceutical companies and home-grown biotechnological start-
ups. The project had an initial fund of $2-billion (1.27- billion €) (Van Epps, 2006). This 
was just the first of the three phases. Phase 1 lasted from 2000 to 2005; the second 
phase from 2006 to 2010 and the third one started in 2011 and ended in 2015. The 
fourth phase has already begun; the fifth phase was already announced. All this 
activities are coordinated by Singapore’s Agency for Science, Technology and 
Research (A*STAR) and the Singapore Economic Development Board (SEDB) (Lim & 
Gregory, 2004). 
 With its entire newly build infrastructure, Singapore serves as a common target for 
outsourcing of contract research and manufacturing. But also clinical research is 
transferred and performed by multi-national companies in Singapore for the Asia 
Pacific market. A high number of global pharmaceutical corporations coordinate 
their Asia Pacific operations from Singapore. Several of these global pharmaceutical 
companies have invested, beside administration and offices, also in R&D on the 
island-country. This investments facilities knowledge spill-overs to local firms and helps 
Singapore transfer itself from a technology adapting location to a technology 
crating nation. As we see on the right chart in the Figure 2, the number of articles is 
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increasing. This indicates more R&D activities. Singapore’s government is investing in 
high end research parks. The largest research park, Biopolis, is located in proximity of 
the National University of Singapore and the National University Hospital. During the 
first phase of BMS, Biopolis was established as a multi-building biotechnological 
complex, which was completed in 2003. More buildings were added in following 
phases of the BMS. To support the R&D operation with local graduates, the 
Singaporean government redesigned the local education system in order to fulfill all 
research needs (Wong et al., 2009). The government provides support for the 
universities by the National Research Foundation (NRF) and the Education Ministry. 
Beside these institutions, Singapore has a plethora of boards and councils to 
encourage the development of the biotechnological industry. The functions and 
capabilities of this institutions range from assistance, starting with fund raising for 
basic R&D and ending with setting up the production of a biotechnological product 
for Start-up Company. These efforts are accompanied by implemented strong 
intellectual property protection laws. The government of Singapore has a bigger 
influence on its biotechnological industry as in the US or Switzerland, but the industry 
is still developing.  
 
Current state of biotechnology sector in selected Eastern 
European countries 
Based on the relative quantity of published scientific articles shown in Figure 3, the 
biotechnological sector in the EE countries is very unevenly developed. The chart in 
Figure 3 is showing how many scientific papers are published per 1000 inhabitants 
per year; this is the same indicator as in Figure 2, right chart. A higher number 
suggests more R&D activity. The best performing country (Slovenia) publishes six times 
more articles in scientific and technical journals than the worst preforming country, 
which is Romania. Such a huge difference is not at all present among the USA, 
Switzerland and Singapore as shown in the previous section (see Figure 2, right 
chart).  
 
Figure 3 Number of published papers in scientific and technical journals per 1000 
inhabitants 
 
Source: WorldBank, 2014c 
 




 The ten countries are clustered into three groups, as can be seen in Figure 3. The 
first group features only Slovenia, the second group includes Estonia and the Czech 
Republic, and the third group includes the rest of the EE countries, which are: 
Bulgaria, Hungary, Lithuania, Latvia, Romanian and the Slovak Republic.  
 The potential of good investments depends on many factors, where the common 
aim is to achieve a fast and sustainable growth. To reach this goal, a successful 
location analysis and selection have to be executed. This is achieved with analyzing 
the macroeconomic and business framework conditions. Factors of importance in 
the process of site selection can be: business sophistication, free trade and 
investment protection agreements, government efficiency, influence of innovation 
on the economy, labor cost, productivity, labor market flexibility, degree of 
workforce internationalization, common prices for goods, services and rents, general 
quality of living, general infrastructure and international air traffic connections. All the 
above mentioned economic factors together with indicator of scientific activity such 
as published scientific publications, can give a better answer for the current state of 
biotechnological in the EE countries.  
 In this section we will compare some of the above mentioned factors and 
indicators for Switzerland, Singapore and the United States with the EE countries. The 
goal is to find similarities and differences, with the purpose to locate gaps and find 
opportunities.  
 
Gross income  
Salary costs can have a high importance on the competitiveness of a site, and 
consequently in the selection process of the location of an investment. In this 
comparison, immense differences are observed between the countries. The 
observed differences are on the gross income level for comparable groups and 
income levels of the workforce. 
 
Table 1 









Bulgaria (Sofia) 18100 9300 5100 
Czech Republic (Prague) 24500 15400 9200 
Hungary (Budapest) 25600 10900 6500 
Estonia (Tallinn) 51000 17900 10600 
Singapore (Singapore) 51693 20177 13203 
Lithuania (Vilnius) 23600 17700 8500 
Latvia (Riga) 23300 15300 9300 
Poland (Warsaw) 20900 13200 8400 
Romania (Bucharest) 13900 7400 5800 
Slovenia (Ljubljana) 56600 17900 12400 
Slovak Republic (Bratislava) 20300 16300 12600 
Switzerland (Zurich) 137200 79800 53200 
US (New York) 118200 79100 41300 
Source: Aisslinger, 2012 
Table 1 shows the gross income per year in USD. The wage levels are representative 
for cities and different groups and levels occupation. Gross income can vary 
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significantly between regions and cities within a country. In Table 1 the highest 
income cities were picket for the given country, this are typically the capital cities, 
the chosen cities are in parenthesis. According to data in Table 1, Romania is most 
favorable, while Switzerland is the most expensive on the list. But foreign exchange 
risks like the Swiss Franc or Romanian Leu against the Euro, have to be taken into 
account. From this point of view, the EE countries that have adopted the Euro have 
a more farmable position.  
 
Productivity & Efficiency 
It is incomplete to consider only the gross incomes to access the effective labor 
expanses. In additional to the gross income level, metrics such as workforce 
efficiency, average annual working hours, holidays and paid vacations, have to be 
considered as well. These factors are summarized in Table 2. 
 
Table 1 









Bulgaria  57 1894 20 
Czech Republic 34 1830 20 
Hungary 56 1976 20 
Estonia  41 1889 20 
Singapore 19 2409 7 
Lithuania  26 1789 20 
Latvia  31 1806 20 
Poland  22 1929 20 
Romania  38 1837 20 
Slovenia 45 1649 20 
Slovak Republic  23 1785 20 
Switzerland 6 1636 20 
USA 5 1787 0 
Source: IMD, 2013 and OECD, 2013 
The first column in Table 2 shows a ranking for “Productivity & Efficiency” based on 
the IMD World Competitiveness Yearbook 2013 (IMD, 2013).The Annual Hours Worked 
per Employed Person is shown in the second column of Table 2 (OECD, 2013). In the 
last column of Table 2, the minimal number of holidays and paid vacations days are 
presented for each given country. 
As Table 2 suggest, the United States together with Switzerland, have one of the most 
productive workforce in the world, thus helping mitigate the high salaries in the US 
and in Switzerland (Table 1). In the US the employers are not obligated to offer paid 
holidays and paid vacations, but otherwise in this category no noticeable 
differences are present. Singapore has the highest working hours in the table 
combined with a high productivity, but Singapore has not the highest productivity. 
Hungary and Poland have relative high number of working hours, compared to 
Slovenia, as the country has a low number of working hours. The productivity is low in 
all EE countries. 
 
 




Higher Education, Labor Market and Venture Capital 
Lower labor costs in combination with the working hours and the proximity of the 
West European markets, can be seen as an advantage in comparison to other low 
cost locations.  
 
Table 2 








Bulgaria  69 61 65 
Czech Republic 39 81 74 
Hungary 44 85 122 
Estonia  23 12 30 
Singapore 2 1 6 
Lithuania  27 69 84 
Latvia  40 26 58 
Poland  37 80 104 
Romania  59 110 92 
Slovenia 25 106 127 
Slovak Republic  58 76 64 
Switzerland 4 2 22 
USA 7 4 3 
Source: WEF, 2014 
The WEF Global Competitiveness Report (WEF, 2014) compares 148 countries in 
different categories, called “pillars” and ranking them. Higher the placements in the 
given pillar better the competitiveness of the country. In Table 3 three pillars on 
higher education, labor market and venture capital for the selected countries are 
shown.  
Higher educated and trained work force is essential for developing a 
biotechnological company, and high-tech companies at general. As shown in Table 
3, the highest rank in higher education and training occupies Singapore. Singapore 
combines a quality higher educational training with a relatively high number of 
students, Figure 1; left chart. Some of the EE countries are ranked quite well, like 
Estonia and Slovenia. As biotechnological companies tend to be smaller and highly 
specialized ventures, an efficient labor market can be an advantage in order to 
recruit the best people. On labor market efficiency, the EE countries rank low in the 
World Economic Forum (WEF) of the Global Competitiveness Report ranking, shown 
in Table 3. Expect Estonia, which is ranked above all EE countries in the ranking for 
labor market efficiency. Typical biotechnological projects tend to be cost intense, as 
a consequence financial markets tent to be an important factor in financing the 
ventures. The venture capital availability ranked by WEF in Table 3, attributes the 
highest ranking position among the EE countries to Estonia. Not surprisingly USA and 
Singapore are leading the list. 
 
Intellectual Property and Suppliers 
The biotechnological industry is R&D-driven by its nature. Purchase or development 
of intellectual property (IP) as well as the production of complex products is of 
central importance. The central questions are where the IP has been or could be 
developed. The following question is profitmaking. This is in more detail where, how 
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and at what stage and price it should be moved from the place of development to 
the place of exploitation. 
From the WEF Global Competitiveness Report(Schwab & Sala-i-Martín, 2014), where 
countries are compared and ranked based on their competitiveness, the categories 
on intellectual property and suppliers are shown in Table 4. The Table 4 shows four 
categories: property rights, intellectual property protection, local supplier quality and 
quality of overall infrastructure. 
Table 4 shows how strongly the intellectual property is protected in each country. In 
this ranking Singapore has the highest position. The US has a surprisingly low ranking 
position, close to Estonia and Romania occupies the lowest position. The picture is 
similar for the overall Property Rights ranking in Table 4, where Estonia is just one 
place behind the USA.  
 
Table 3 










Quality of overall 
infrastructure 
Bulgaria  111 104 72 102 
Czech Republic 88 61 21 37 
Hungary 103 58 70 49 
Estonia  34 31 25 33 
Singapore 2 2 28 5 
Lithuania  71 66 34 44 
Latvia  62 51 53 50 
Poland  66 72 51 84 
Romania  82 110 104 106 
Slovenia 69 42 33 31 
Slovak Republic  83 65 41 81 
Switzerland 3 5 1 1 
USA 33 25 10 19 
Source: Schwab & Sala-i-Martín, 2014 
The attractiveness of a location for an investment as a R&D-site or production is 
characterized with a good access for supplies. Two rankings try to describe this in 
Table 4 named “Local supplier quality” and “Quality of overall infrastructure”. 
Switzerland is ranked best in both categories. The top scores among the EE countries 
belong to Slovenia, Estonia and the Czech Republic. In the above cases, the lack of 
international flight connections is dragging down the ranking of the EE countries. 
 
Development of biotechnology sector in selected Eastern 
European countries: Causes of current state and future 
directions 
Causes of underdevelopment of biotechnological sector 
The reasons for a low level of investments in biotechnology among the EE countries 
are divers. They range from shared history to difficulties to access financing in recent 
times. In this section we will first discus the historical heritage and then proceed to 
more recent challenges. 




 Cause 1: Former centrally planned economies. The former centrally planned 
economies of the EE countries were of a closed nature. In consequence their 
scientific community did not want or could not take part in the international scientific 
discussion and R&D community exchange (Radosevic & Auriol, 1999). Scientific 
results were not always published in English journals. This hindered the international 
communication of scientific results. Moreover, in the epoch of centrally planned 
economy, the science funding focused around some scientific fields, like physics and 
chemistry, biosciences were in this circumstances underrepresented (Kozlowski et al., 
1999). The reason to neglect research in biosciences originated from at least two 
reasons; (1) most government encouragement was focused on research areas that 
could serve the military/industrial complex and (2) basic and theory oriented topics 
were favored in order to minimize the dependents of expensive equipment. 
Biosciences cannot fulfill these two criteria, because it requires costly research and 
experimental work (Senker et al., 2012). 
 Cause 2: Political instability during the period of transition. The former centrally 
planned economies appeared in a period of transition, starting 1989. The transition 
involved the transformation of a centrally planned economy to an open market 
economy. As a consequence, these transitions brought some political instability, 
which had an impact on foreign direct investment(Brada et al., 2006). In some EE 
countries a consequence of this transition period resulted in sporadically formed 
biotechnology-related capacities as well as infrastructure and resource 
deteriorated. This deterioration was initiated because of the drastically reduced 
demand in the Eastern Bock. This collapsed market in the Eastern Bock was 
combined, with the inability to enter new markets(Senker et al., 2012).  
 Cause 3: Higher education and training is lagging behind. As the above historical 
overview summarizes, biotechnological is not historically anchored in this region. But 
as biotechnological is, in essence, a new science based industry; its beginnings 
should be found at institutions of higher education. Such as academic start-ups or 
spin-off companies from universities. Highly educated and specialized staff is needed 
for biotechnological companies. The low number of biotechnological companies 
can be explained on the basis of international ranking of higher education and 
training. Higher education and training is lagging behind in the EE, the exceptions 
being Estonia, Slovenia and Lithuania as shown in Table 3. All these three countries 
are also ranking 16 places behind the USA, which is the bottom among the 
developed regions in this respect. This gap can be critical for high tech industries, like 
biotechnological.  
 Cause 4: Poor efficiently of the labor market. Perhaps university graduates are not 
the best choice for certain projects, as they are too inexperienced. At this point, an 
efficiently working labor market is crucial in finding and recruiting the best talents 
possible. In Table 3, the ranking positions for the EE countries and the three 
developed markets are represented. Except Estonia and Latvia, all EE countries have 
low rankings. Singapore and Switzerland are here leading the list. Additionally to 
human capital, venture capital availability can be crucial to set up a risky high tech 
venture. Each country’s venture capital availability is presented in Table 3. The 
overall picture is similar to higher education and training ranking as well as labor 
market efficiency. Singapore, Switzerland and the US are at the top of the list and 
the EE countries are at the bottom. Estonia has the leading position among the EE 
countries. 
 Cause 5: Insufficient intellectual property protection. High tech ventures like 
biotechnological are sensitive to intellectual property protection. Rankings in Table 4 
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are suggesting a gap between the EE countries and the developed regions. Estonia 
yet again is being the exception, whilst ranking close to the US.  
The overall picture suggests that biotechnological is not historically present in the EE 
countries and that the current conditions are not in any way encouraging. The 
described business environment combined with an inefficient government 
bureaucracy is hindering start-ups (Kochanova, 2012; Mungiu-pippidi, 2014). In 
addition, difficult access to financing is hindering the innovators on their way to 
success.  
 
Recommended strategy for the development of biotechnology sector  
The entire group of the EE countries ranked low in Table 4 (Property rights and 
Intellectual property protection). The score is also low on “Venture capital 
availability” in Table 3. This all speaks against establishing a capital intense and 
intellectual property based business. On the other hand, data from Table 2, about 
wages, together with the scores in “Higher education and training” makes the region 
attractive again. The wages are low in comparison to Western Europe; this fact in 
turn can favor a production site with labor intense tasks. The relatively high score in 
some EE countries regarding “Higher education and training” suggest that highly 
educated graduates are available.  
Beside the personal, raw materials have to be obtained and transported. For these 
tasks the following two metrics can be used: (1) the Local supplier quality and the (2) 
Quality of overall infrastructure from Table 4. The relatively low scores on “Quality of 
overall infrastructure” are largely tied with weaker international flight connections. 
But because of the proximity of the big West European airport hubs, the accessibility 
is still adequate. Raw materials can be obtained locally, as the scores under “Local 
supplier quality” suggest, this further reduces the costs of production. The 
geographical proximity of the major European markets for biotechnological 
products makes the EE countries attractive.  
 Recommendation 1: Transfer of production and research capabilities. All these 
above mentioned advantages show in the direction for a competitive cost of 
production. The gained advantage is compared with expensive and developed 
biotechnological locations like Switzerland. Production transfers to an EE country or 
even the transfer of a research to a Contract Research Organizations in the EE 
countries could give a competitive cost advantage. The transfer of production or 
part of the research process could give the local economy a know-how spillover. 
Knowledge could be transferred from the foreign companies to the local ones. This 
spillover effects could accelerate further investments in the region, and benefit both 
the EE countries with new jobs and the investor with higher profits. 
 Recommendation 2: Creating formal academic alliances. The aim by seeking 
formal academic connections is transfer of world class basic science. Investment in 
basic research could transform the EE countries from a technology adapting, to a 
technology creating region. Formal academic cooperation would foster a 
permanent communication between institutions on all levels. The aim would be to 
create a strong presence of the world class universities, such as Harvard, Cambridge 
and Stanford in the EE countries. And vice versa, the universities from the EE countries 
should establish a presence in research parks and technology centers (like Silicon 
Valley) around the world to transfer people and knowledge. 
 Recommendation 3: Good governance. Beside the above mentioned the EE 
countries should future exploit after adopting democracy, how could the EE 
countries adopt governance from the West and the EU. The aim should be to 




reducing the inefficient government bureaucracy. The resulting government 
bureaucracy would help start-ups and small high-tech business to grow rapidly.  
 Recommendation 4: Strengthen intellectual property protection. As the EE 
countries are showing some weaknesses in the intellectual property protection 
department, this should be upgraded, as this is crucial for high tech industries like 
biotechnological.  
 Recommendation 5: Include the civil society. But not forget about the civil society 
- the consumers and non-governmental organization. New technologies need the 
support from the society to get accepted and spared. Only when the new 
technology is perceived by the public in a positive light, will the community easily 
cooperate on large projects.  
 All the data from the previous sections shows different stage of development of 
the EE countries. Because of this, the solutions have to be unique for every region, 
with the aim to stenting the strengths and eradicate weaknesses. 
 
Conclusion 
Biotechnology bears the potential for a long-lasting community development, with 
the opportunity of job creation. For a region with a disproportional high youth 
unemployment (Kolev & Saget, 2005). Exploring a high technology sector could give 
the possibility of highly paid occupations and reduce unemployment. But the sector 
bears high risks, since the R&D-phase for a product can frequently exceed 10 years 
and no profits are generated during this period (Adelman & Holman, 2009). This 
creates subsequent uncertainty of success in a rapidly changing market 
environment, where the products can rapidly get obsolete.  
 
Summary of the research 
The EE countries cannot rely solely on tier low-wage advantage over West European 
production locations. Over time the wage advantage can lessen and these 
advantages can diminish. A way to make the EE countries more competitive would 
be invest in productivity & efficiency of the production. This kind of investments could 
be leveraged by infrastructure investments and know-how spillovers of foreign 
multinational companies. After the production and R&D infrastructures are build, the 
EE countries should focus on their own entrepreneurs (Farrell, 2005).  
 To be able for fully utilize their production and R&D infrastructure. All parties from 
industry, government to academia must cooperate to achieve the best possible 
result (Debackere & Veugelers, 2005). Such cooperation has to be coordinated. The 
coordination must be led by an organization with a high reputation. In certain cases 
this roll can be fulfilled by the government, in a good governance way. New 
concepts or principles with market potential have to be recognized and protected; 
for this task intellectual property protection rules are needed. 
 The advantages, which are speaking for the region, are following: the proximity to 
Western Europe, relatively long working hours per year, relatively highly educated 
work force and its low labor costs. The relatively weak intellectual property 
protection can serve as an advantage in generic and biosimilar production 
circumstances (Walsh, 2014). 
 The regulators of the EE countries have to find the right balance of regulation to 
create an environment of cooperation between research institutions, industry and 










Biotechnological industry promises high returns for those, who participate in it 
(Grullon et al., 2012). To obtain such high returns, a physical infrastructure must be 
present. The EE courtiers have to transfer from an adopting technology approach, to 
a creating technology approach, or even focus to lead in certain technological 
areas. The prerequisite for creating and lead in technology is R&D. A high-end R&D 
infrastructure has to be built to attract and leverage the best possible talent. 
 The EE countries have to cooperate with the international technology markets, 
dominated by North American and Western European firms. The entrepreneurs from 
the EE countries have to find their niches and try to obtain the leading position with 
innovation (Kim & Mauborgne, 2004). The EE countries should find a way to enhance 
and foster an entrepreneurial spirit on their universities, business incubator facilities, 
academic spin-off initiatives and other research institutions (Meyer, 2003). The 
government could give support and monitor the process. Patenting and licensing of 
technologies as well as join R&D projects between private firms and public research 
institutions could serve as indicators to follow the success. 
 
Limitations and future research 
This paper provides just a snap shot of the current situation. Biotechnology is evolving 
rapidly, data can render rapidly obsolete. The EE courtiers were treated in this paper 
as one entity, but in many aspects this is not true. There a huge differences on many 
levels between the countries.  
 Regions with a well-developed biotechnology business sector are evolving. More 
and different regions a becoming successful in biotechnology and the reference list 
from the beginning of this paper can become inadequate. 
Despite the limitation of this paper to put a heterogeneous group of the EE countries 
together, common challenges could be found. A common challenge does not 
mean that the same solution fits all needs. To give an efficient recommendation 
every country or region with in the country should be treated separately. 
 The future research should explore the way of international academic 
cooperation. The universities form the EE countries should seek a strong linkage to 
foreign academic institutions and domestic industry. Explore routes for better 
governance and ways how to strengthen intellectual property protection. In this 
journey of technological transition, the support of the civil society is needed. Future 
research could explore ways to get the support of the civil society. 
 At last, the stories of the three successful biotechnological regions, from the 
beginning, are very different. There is no universal recipe to success, so every 
community has to find its own way to sustained prosperity - biotechnological could 
be one answer.  
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